Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Innovent Biologics Inc

1801
Current price
39.55 HKD +0.55 HKD (+1.41%)
Last closed 35.05 HKD
ISIN KYG4818G1010
Sector Healthcare
Industry Biotechnology
Exchange Hong Kong Stock Exchange
Capitalization 63 100 887 036 HKD
Yield for 12 month -18.29 %
1Y
3Y
5Y
10Y
15Y
1801
21.11.2021 - 28.11.2021

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China. Address: 168 Dongping Street, Suzhou, China, 215123

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

427.62 HKD

P/E ratio

Dividend Yield

Current Year

+6 795 996 344 HKD

Last Year

+4 989 492 841 HKD

Current Quarter

+2 958 329 764 HKD

Last Quarter

Current Year

+5 551 721 047 HKD

Last Year

+3 970 006 331 HKD

Current Quarter

+2 405 747 909 HKD

Last Quarter

Key Figures 1801

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -990 617 021 HKD
Operating Margin TTM -10.94 %
PE Ratio
Return On Assets TTM -4.18 %
PEG Ratio
Return On Equity TTM -11.04 %
Wall Street Target Price 427.62 HKD
Revenue TTM 7 456 828 928 HKD
Book Value 7.63 HKD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 46.3 %
Dividend Yield
Gross Profit TTM 3 174 627 000 HKD
Earnings per share
Diluted Eps TTM
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin -17.18 %

Dividend Analytics 1801

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 1801

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 1801

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.3272
Price Sales TTM 8.4622
Enterprise Value EBITDA -19.7145
Price Book MRQ 4.2062

Financials 1801

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 1801

For 52 weeks

28.3 HKD 52.15 HKD
50 Day MA 43.66 HKD
Shares Short Prior Month
200 Day MA 39.55 HKD
Short Ratio
Shares Short
Short Percent